Studies have found that in the treatment of cervical cancer, the combined use of CMNa has higher levels of CD3+, CD4+, CD4+/CD8+ (P < 0.05), and lower CD8+ levels (P < 0.05) compared with the radio-chemotherapy group alone. The gene discussed is CD8A; the disease is cervical cancer.